NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. (“Uroplasty” or “the Company”) (NasdaqCM: UPI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM: VSCI).
Click here to learn more about the investigation: http://zlk.9nl.com/uroplasty.
Under the terms of the transaction, Uroplasty shareholders will receive 3.6331 shares of Vision-Sciences common stock for each share of Uroplasty stock they own. The investigation concerns whether the Board of Uroplasty breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Vision-Sciences, Inc. is underpaying for Uroplasty shares. The combined company will conduct business as Cogentix Medical, Inc. (Nasaq: CGNT).
If you own Uroplasty common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/uroplasty.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.